At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 22 enrolled
Drug / intervention
RV001Vbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Study of RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours
In Brief
A Phase 2 clinical trial evaluating RV001V for Prostate Cancer. Completed, enrolled 22 participants across 1 site.
Detailed Summary
The study will evaluate safety and immunological response to RhoC peptide vaccine in patients with prostate cancer
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesDenmark
CollaboratorsDantrials Aps
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartMar 2017
First PostedJun 2017
Primary CompletionAug 2018
Study CompletionMar 2019
TodayJul 2026
First PostedJun 27, 2017
Enrollment StartMar 30, 2017
Primary CompletionAug 1, 2018
Study CompletionMar 29, 2019
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 9.0 years ago
Interventions
RV001Vbiological
Sc injection